Terminated
PHASE3
INTERVENTIONAL
NCT00133224
Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The primary objective of this study is to compare the duration of survival between patients receiving docetaxel in combination with the GVAX® vaccine for prostate cancer versus patients receiving docetaxel and prednisone treatment in patients with prostate cancer who no longer respond to hormone therapy, who have documented metastases with pain. Patients may have had up to one prior non-taxane chemotherapy treatment.
Interventions
Name:
Immunotherapy allogeneic GM-CSF secreting cellular vaccine
Type:
BIOLOGICAL
Description:
Immunotherapy allogeneic GM-CSF secreting cellular vaccine
Name:
Chemotherapy (docetaxel and prednisone)
Type:
DRUG
Description:
Chemotherapy (docetaxel and prednisone)
Primary Outcomes
Measure:
Survival
TimeFrame:
0
Description:
Trial Information
NCT ID
NCT00133224
Status
Terminated
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Cell Genesys
Last Updated
December 15, 2025